These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 27029491)

  • 1. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
    Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
    Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.
    Rasche L; Duell J; Castro IC; Dubljevic V; Chatterjee M; Knop S; Hensel F; Rosenwald A; Einsele H; Topp MS; Brändlein S
    Haematologica; 2015 Mar; 100(3):377-84. PubMed ID: 25637055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.
    Rasche L; Duell J; Morgner C; Chatterjee M; Hensel F; Rosenwald A; Einsele H; Topp MS; Brändlein S
    PLoS One; 2013; 8(5):e63414. PubMed ID: 23667612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
    Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
    Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78.
    Rosenes Z; Mulhern TD; Hatters DM; Ilag LL; Power BE; Hosking C; Hensel F; Howlett GJ; Mok YF
    PLoS One; 2012; 7(9):e44927. PubMed ID: 23028685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
    Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
    Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
    Oka S; Ono K; Nohgawa M
    J Clin Pharm Ther; 2018 Dec; 43(6):914-917. PubMed ID: 29974481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
    Benson DM; Cohen AD; Jagannath S; Munshi NC; Spitzer G; Hofmeister CC; Efebera YA; Andre P; Zerbib R; Caligiuri MA
    Clin Cancer Res; 2015 Sep; 21(18):4055-61. PubMed ID: 25999435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab combination prolongs myeloma survival.
    Das M
    Lancet Oncol; 2016 Oct; 17(10):e422. PubMed ID: 27601427
    [No Abstract]   [Full Text] [Related]  

  • 14. Early development of PAT-SM6 for the treatment of melanoma.
    Hensel F; Eckstein M; Rosenwald A; Brändlein S
    Melanoma Res; 2013 Aug; 23(4):264-75. PubMed ID: 23728394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
    Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T; Eid JE; Houp J; Gause C; Vuocolo S; Anderson KC
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):329-334.e1. PubMed ID: 27025160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
    Richardson PG; Beksaç M; Špička I; Mikhael J
    Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous binding of the anti-cancer IgM monoclonal antibody PAT-SM6 to low density lipoproteins and GRP78.
    Rosenes Z; Mok YF; Yang S; Griffin MD; Mulhern TD; Hatters DM; Hensel F; Howlett GJ
    PLoS One; 2013; 8(4):e61239. PubMed ID: 23620733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
    Gross Z; Rahbari A; Wirtschafter E; Spektor TM; Udd KA; Bujarski S; Ghermezi M; Nosrati JD; Vidisheva A; Eades B; Cecchi G; Maluso T; Swift R; Berenson JR
    Eur J Haematol; 2018 Jun; 100(6):621-623. PubMed ID: 29524348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
    Wudhikarn K; Wills B; Lesokhin AM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.